0.03
+24900.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vaxxinity
Its shares trade under the ticker VAXX. It has been listed since 11 November 2021. In the fiscal year to 31 December 2022, it reported revenue of −$1,000 and a net loss of $75.2m. At that date it held total assets of $106.4m and shareholders' equity of $62.2m.
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Nov 2021
- Employees
- 87
- Website
- vaxxinity.com ↗
Leadership
Pay as last reported
- Mr. Louis ReeseExecutive Chairman$1.3m
- Ms. Mei Mei HuPresident, Chief Executive Officer, Co-Founder, Director$1.4m
- Mr. Jason PesileChief Accounting Officer
- Ms. Sumita RayChief Legal, Compliance and Administrative Officer$500,907
- Mr. Landon OgilvieLead Independent Director$270,621
- Dr. Peter DiamandisIndependent Director$233,936
- Mr. George HornigIndependent Director$264,153
- Mr. James SmithIndependent Director$249,986
- Ms. Gabrielle ToledanoIndependent Director$259,986
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 39
- Social
- 66
- Governance
- 14
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vaxxinity Inc's Vaxxine Platform enables innovative vaccine development for chronic diseases like Alzheimer's and Parkinson's.
- The company's pipeline includes six programs targeting Alzheimer's, Parkinson's, and migraines with specific candidates.
- Vaxxinity's focus on chronic diseases with unmet medical needs positions it in a growing market segment.
Weaknesses
- Vaxxinity has only 87 employees, which may limit its operational capacity and research scale.
- The company's IPO in November 2021 indicates a relatively new market presence with limited financial history.
- Vaxxinity's pipeline candidates are still in development, lacking clinical trial data for validation.
Opportunities
- The growing market for chronic disease treatments offers significant potential for Vaxxinity's pipeline candidates.
- Vaxxinity's focus on Alzheimer's and Parkinson's aligns with increasing global health priorities.
- The company's synthetic peptide vaccine platform could expand into new therapeutic areas beyond current targets.
Threats
- Competition from established biotech firms in the Alzheimer's and Parkinson's treatment markets.
- Regulatory hurdles and lengthy approval processes for new vaccine-based therapies.
- Financial risks associated with ongoing research and development costs for multiple pipeline programs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.